As of March 18, Hans Clevers, Oncode Investigator and one of Oncode’s founding scientists, will head Roche Pharmaceutical Research and Early Development (pRED) and become a member of the Corporate Executive Committee at Roche in Basel, Switzerland. In this new role, he will lead research into the development of drugs for a wide variety of diseases. Hans will stay closely connected to the Oncode research community.
He will also stay involved with his research group at the Hubrecht Institute as an advisor/guest researcher.
Hans Clevers says: “After working more than 40 years with fantastic colleagues in academic laboratories, my passion for science is undiminished. I hope to use the knowledge I obtained in these years to contribute to the development of essential, accessible drugs at Roche.”
Geert Kops, head of Oncode Institute says: “We congratulate Hans on this exciting new step in his illustrious career. We are thankful for his many contributions to our institute and look forward to keep interacting with him and his team.”
Hans started his career by studying biology and medicine in Utrecht, with the goal to become a doctor and help patients. During his PhD however, he discovered his great passion for science and research and decided to continue in academia. In the years since, his research has led to many discoveries and his work is cited and built upon all over the world. After doing research in the US and the UMC Utrecht, Hans came to the Hubrecht Institute in 2002, where he developed organoid technology, now used by countless labs around the world to study a wide variety of organs and diseases. In 2017, he co-founded Oncode Institute, with the aim to bring more basic science discoveries to cancer patients faster. By heading pRED, Hans now comes full circle, aiming to help patients get better by leading the development of new drug treatments at Roche.
More information
Read the full press release on the Roche website
Read an interview with Hans about his new role in the Financieele Dagblad
Biography
Hans Clevers is MSc in Biology, MD and obtained his PhD at the University of Utrecht. He is currently a university professor at Utrecht University and group leader at the Hubrecht Institute and the Princess Máxima Center for pediatric oncology and Oncode Investigator. In addition, he serves on several scientific advisory boards, including the Francis Crick Institute, and is a co-founder of several companies. He is a member of the Royal Dutch Academy of Sciences, the National Academy of Science in the United States, the Academy of Science in France and The Royal Society in the United Kingdom. Hans Clevers has been involved with Roche on the Board of Directors since 2019.
